Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/16671
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHersey, P.en
dc.contributor.authorMenzies, S.en
dc.contributor.authorCoventry, B.en
dc.contributor.authorNguyen, T.en
dc.contributor.authorFarrelly, M.en
dc.contributor.authorCollins, S.en
dc.contributor.authorHirst, D.en
dc.contributor.authorJohnson, H.en
dc.date.issued2005en
dc.identifier.citationCancer Immunology Immunotherapy, 2005; 54(3):208-218en
dc.identifier.issn0340-7004en
dc.identifier.issn1432-0851en
dc.identifier.urihttp://hdl.handle.net/2440/16671-
dc.description© Springer-Verlag 2004en
dc.description.abstractPrevious studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by T cells could induce regression of melanoma. This approach was tested in 36 patients with stage IV melanoma. The (MHC class I– restricted) peptides were from gp100, MART-1, tyrosinase, and MAGE-3. The gp100 and MART-1 peptides had been modified to increase their immunogenicity. In half the patients (groups 3 and 4) the peptides were given in the adjuvant Montanide-ISA-720, and half the patients in both groups were given GM-CSF s.c. for 4 days following each injection. Treatment was well tolerated except for two severe erythematous responses to Montanide- ISA-720 and marked inflammatory responses at sites of GM-CSF administration in three patients. There were no objective clinical responses but stabilization of disease for periods from 3 to 12 months were seen in seven patients. Five of these were patients given the peptides in Montanide-ISA-720. Delayed-type hypersensitivity (DTH) skin test responses were also seen mainly in the patients given the peptides in Montanide- ISA-720. GM-CSF did not increase DTH responses in patients in the latter group but may have increased DTH responses in those not given peptides in Montanide-ISA- 720. Inflammatory responses around s.c. metastases or regional lymph nodes were observed in two patients. These results suggest that the peptides are more effective when given in the adjuvant Montanide-ISA-720. Nevertheless, results from this study, together with those from a number of comparable studies, indicate that peptide vaccines are currently of minimal benefit to patients and support the need for ongoing development of new strategies in treatment of this disease.en
dc.description.statementofresponsibilityPeter Hersey, Scott W. Menzies, Brendon Coventry, Tam Nguyen, Margaret Farrelly, Susan Collins, Debbie Hirst and Heather Johnsonen
dc.language.isoenen
dc.publisherSpringer-Verlagen
dc.subjectAdjuvants; Clinical responses; Melanoma; Peptide vaccines; T-cell responsesen
dc.titlePhase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanomaen
dc.typeJournal articleen
dc.identifier.rmid0020050031en
dc.identifier.doi10.1007/s00262-004-0587-8en
dc.identifier.pubid55352-
pubs.library.collectionSurgery publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidCoventry, B. [0000-0002-3596-7735]en
Appears in Collections:Surgery publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.